Bicycle Therapeutics plc Lease, Cost
Bicycle Therapeutics plc (BCYC) reported Lease, Cost of $2.12 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2024-10-31
- Bicycle Therapeutics plc lease, cost for the quarter ending 2024-09-30 was $2.12M, a 9.59% increase year-over-year.
- Bicycle Therapeutics plc lease, cost for the quarter ending 2024-06-30 was $1.90M, a 12.40% decline year-over-year.
- Bicycle Therapeutics plc lease, cost for the quarter ending 2024-03-31 was $2.12M, a 7.50% increase year-over-year.
- Bicycle Therapeutics plc lease, cost for the quarter ending 2023-12-31 was $2.11M, a 35.15% increase year-over-year.
- Bicycle Therapeutics plc lease, cost for fiscal 2023 was $8.19M, a 50.65% increase from fiscal 2022.
- Bicycle Therapeutics plc lease, cost for fiscal 2022 was $5.43M, a 195.92% increase from fiscal 2021.
- Bicycle Therapeutics plc lease, cost for fiscal 2021 was $1.84M, a 17.84% increase from fiscal 2020.
- Bicycle Therapeutics plc lease, cost for fiscal 2020 was $1.56M, a 20.78% increase from fiscal 2019.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.12M 10-Q · filed 2024-10-31 | $4.02M derived: sum of 2 quarters · filed 2024-10-31 | $6.14M 10-Q · filed 2024-10-31 | $8.25M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | $1.90M 10-Q · filed 2024-08-06 | $4.02M 10-Q · filed 2024-08-06 | $6.13M derived: sum of 3 quarters · filed 2024-08-06 | $8.06M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-03-31 | $2.12M 10-Q · filed 2024-05-02 | $4.23M derived: sum of 2 quarters · filed 2024-05-02 | $6.16M derived: sum of 3 quarters · filed 2024-10-31 | $8.33M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $4.04M derived: sum of 2 quarters · filed 2024-10-31 | $6.21M derived: sum of 3 quarters · filed 2024-10-31 | $8.19M 10-K · filed 2024-02-20 |
| 2023-09-30 | $1.93M 10-Q · filed 2024-10-31 | $4.10M derived: sum of 2 quarters · filed 2024-10-31 | $6.07M 10-Q · filed 2024-10-31 | $7.64M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $2.17M 10-Q · filed 2024-08-06 | $4.14M 10-Q · filed 2024-08-06 | $5.71M derived: sum of 3 quarters · filed 2024-08-06 | $7.04M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.97M 10-Q · filed 2024-05-02 | $3.54M derived: sum of 2 quarters · filed 2024-05-02 | $4.87M derived: sum of 3 quarters · filed 2024-05-02 | $6.23M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $2.90M derived: sum of 2 quarters · filed 2024-02-20 | $4.26M derived: sum of 3 quarters · filed 2024-02-20 | $5.43M 10-K · filed 2024-02-20 |
| 2022-09-30 | $1.33M 10-Q · filed 2023-11-02 | $2.70M derived: sum of 2 quarters · filed 2023-11-02 | $3.87M 10-Q · filed 2023-11-02 | $4.49M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.36M 10-Q · filed 2023-08-03 | $2.54M 10-Q · filed 2023-08-03 | $3.16M derived: sum of 3 quarters · filed 2024-02-20 | $3.65M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $1.17M 10-Q · filed 2023-05-04 | $1.79M derived: sum of 2 quarters · filed 2024-02-20 | $2.29M derived: sum of 3 quarters · filed 2024-02-20 | $2.70M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $619.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.11M derived: sum of 2 quarters · filed 2024-02-20 | $1.53M derived: sum of 3 quarters · filed 2024-02-20 | $1.84M 10-K · filed 2024-02-20 |
| 2021-09-30 | $495.00K 10-Q · filed 2022-11-03 | $911.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.22M 10-Q · filed 2022-11-03 | $1.66M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $416.00K 10-Q · filed 2022-08-04 | $727.00K 10-Q · filed 2022-08-04 | $1.16M derived: sum of 3 quarters · filed 2023-02-28 | $1.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $312.00K 10-Q · filed 2022-05-05 | $745.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.12M derived: sum of 3 quarters · filed 2023-02-28 | $1.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $812.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.20M derived: sum of 3 quarters · filed 2023-02-28 | $1.56M 10-K · filed 2023-02-28 |
| 2020-09-30 | $379.00K 10-Q · filed 2021-11-04 | $763.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.13M 10-Q · filed 2021-11-04 | $1.46M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $384.00K 10-Q · filed 2021-08-05 | $746.00K 10-Q · filed 2021-08-05 | $1.08M derived: sum of 3 quarters · filed 2022-03-01 | $1.40M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $362.00K 10-Q · filed 2021-05-06 | $701.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.01M derived: sum of 3 quarters · filed 2022-03-01 | $1.32M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $649.00K derived: sum of 2 quarters · filed 2022-03-01 | $960.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.29M 10-K · filed 2022-03-01 |
| 2019-09-30 | $310.00K 10-Q · filed 2019-11-07 | $621.00K derived: sum of 2 quarters · filed 2019-11-07 | $951.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $311.00K 10-Q · filed 2019-08-08 | $616.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |